Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10199464rdf:typepubmed:Citationlld:pubmed
pubmed-article:10199464lifeskim:mentionsumls-concept:C0009452lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0221464lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0205054lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0021735lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C1521733lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:10199464lifeskim:mentionsumls-concept:C0699666lld:lifeskim
pubmed-article:10199464pubmed:issue2lld:pubmed
pubmed-article:10199464pubmed:dateCreated1999-4-15lld:pubmed
pubmed-article:10199464pubmed:abstractTextThe case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs.lld:pubmed
pubmed-article:10199464pubmed:languageenglld:pubmed
pubmed-article:10199464pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:citationSubsetIMlld:pubmed
pubmed-article:10199464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10199464pubmed:statusMEDLINElld:pubmed
pubmed-article:10199464pubmed:monthAprlld:pubmed
pubmed-article:10199464pubmed:issn0277-3732lld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:PattY ZYZlld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:Charnsangavej...lld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:EllisLLlld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:RobCClld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:LozanoRRlld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:CarrascoC HCHlld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:ClearyKKlld:pubmed
pubmed-article:10199464pubmed:authorpubmed-author:HoqueAAlld:pubmed
pubmed-article:10199464pubmed:issnTypePrintlld:pubmed
pubmed-article:10199464pubmed:volume22lld:pubmed
pubmed-article:10199464pubmed:ownerNLMlld:pubmed
pubmed-article:10199464pubmed:authorsCompleteYlld:pubmed
pubmed-article:10199464pubmed:pagination209-13lld:pubmed
pubmed-article:10199464pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:meshHeadingpubmed-meshheading:10199464...lld:pubmed
pubmed-article:10199464pubmed:year1999lld:pubmed
pubmed-article:10199464pubmed:articleTitleDurable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.lld:pubmed
pubmed-article:10199464pubmed:affiliationDepartment of Gastrointestinal Medical Oncology and Digestive Diseases, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.lld:pubmed
pubmed-article:10199464pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10199464pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:10199464pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199464lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199464lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10199464lld:pubmed